Market evolution: Infusion sets (CN 90189050) — 2015–2025

Introduction

This report examines the evolution of EU extra-Union trade in transfusion and infusion apparatus (CN 90189050) over the 2015–2025 period. The product, which covers devices essential for intravenous therapy, blood transfusion, and clinical nutrition, sits within the broader category of medical instruments and appliances (chapter 90). Over the decade under review, the EU market for this product has undergone a pronounced expansion, both in terms of trade volumes and values. EU exports nearly doubled in value while imports grew even faster, yet the Union has consolidated its position as a strong net exporter. Several structural shifts — including the re-routing of supply chains, the impact of the COVID-19 pandemic, and the rapid growth of intra-EU redistribution hubs — define the period. The analysis below draws on trade data at the annual frequency, covering flows between the EU and non-EU countries.

Source: Scope & Definitions

1. A decade of sustained growth that accelerated after 2020

1.1 EU exports nearly doubled in value while outpacing volume growth

Over the 2015–2025 period, EU extra-Union exports of infusion sets rose from €453.2 million to €896.8 million, representing a cumulative increase of 97.9%. Physical export volumes grew more moderately, from 13,477 tonnes to 18,391 tonnes (+36.5%). The gap between value and volume growth is explained by a significant rise in unit export prices, which climbed from €33,625/t to €48,759/t (+45.0%). This price increase reflects both a shift toward higher-value products and broader inflationary pressures over the period.

1.2 Import growth was even faster, driven by volume rather than price

EU imports of infusion sets from non-EU countries grew from €225.0 million to €501.4 million (+122.9%), with physical volumes rising from 13,562 tonnes to 21,116 tonnes (+55.7%). Import prices increased from €16,590/t to €23,746/t (+43.1%), broadly in line with export price dynamics. Notably, the EU's import unit values remain roughly half the level of export unit values, consistent with the sourcing of lower-cost components and standardised products from Asia, while the EU exports higher-specification or branded devices.

1.3 The EU trade surplus widened significantly

Despite faster import growth in percentage terms, the EU's trade surplus in this product expanded from €228.2 million to €395.3 million (+73.3%). In relative terms, the net import reliance shifted from −7.1% to −37.7%, confirming that the EU has moved from a position of near-balance to one of strong net export dependence. The export propensity — the share of EU production that is exported outside the Union — surged from 27.3% to 70.7%, and trade intensity nearly doubled from 39.8% to 79.6%, indicating a market that has become deeply integrated into global flows.

Source: General Overview — Trade

2. Geographic reconfiguration of both supply and demand

2.1 Import sources diversified, with China consolidating its lead and new suppliers emerging

The concentration of EU imports, measured by the Herfindahl-Hirschman Index (HHI) on value, declined from 1,743 to 1,162 (−33.3%), indicating meaningful diversification of the EU's supplier base. China remained the dominant import source throughout the period, growing from €52.0 million to €100.7 million (+93.6%). However, the most dramatic change came from the Dominican Republic, which saw EU imports surge from €4.2 million to €64.0 million (+1,412.7%), and from Malaysia, which nearly doubled from €16.1 million to €32.0 million (+98.8%). These trends likely reflect the expansion of free-trade-zone manufacturing in the Caribbean and Southeast Asia. Meanwhile, imports from the United States remained essentially flat at around €66 million, and Tunisia — a traditional nearshore supplier — saw its share decline (−47.6%).

2.2 The United Kingdom and the United States became the EU's dominant export markets

On the export side, the United Kingdom and the United States emerged as the two largest non-EU destinations. Exports to the UK grew from €46.7 million to €150.7 million (+222.5%), partly reflecting post-Brexit trade reclassification of what were previously intra-EU flows. Exports to the US rose from €52.8 million to €162.8 million (+208.1%). Australia also showed striking growth (€10.7M → €36.9M, +243.2%). Russia, traditionally a major destination, grew only modestly (€44.5M → €50.3M, +13.0%), with volumes likely constrained by geopolitical factors and sanctions from 2022 onwards. Export HHI increased from 535 to 807 (+50.9%), reflecting a moderate concentration toward a few large markets.

2.3 Within the EU, Germany remained the production powerhouse while the Netherlands and Poland surged

The member-state breakdown reveals a significant redistribution of trade shares within the Union. Germany was the largest exporter throughout, contributing €286.5 million in 2015 and €299.3 million in 2025 (+4.4%), but its share of EU exports eroded as others grew faster. The Netherlands experienced extraordinary growth in both exports (€31.1M → €188.7M, +507.6%) and imports (€6.4M → €129.4M, +1,920.4%), consistent with its role as a logistics and redistribution hub — likely driven by the consolidation of medical device distribution through Dutch ports. Poland also grew rapidly on both sides: exports from €9.0M to €81.1M (+798.6%) and imports from €5.8M to €61.4M (+965.8%), suggesting the emergence of manufacturing capacity in Central Europe. France similarly expanded its export footprint (€23.3M → €72.9M, +213.3%).

Source: General Overview — Top reporters

3. COVID-19 as a structural inflection point for production and trade patterns

3.1 The pandemic triggered sharp price shocks in key bilateral flows

The volatility and shock analysis reveals that the most significant trade anomalies clustered around 2020. A major export price shock was detected in EU-US trade in 2020, with an abnormality score of 19.1 and a price shift of +34.8%, affecting flows that represented 18.3% of total export value. Simultaneously, EU imports from Malaysia experienced a price shock (abnormality 10.4, +84.9% price shift), accounting for 12.4% of import value. A secondary shock was detected in EU-South Africa exports in 2021 (+26.4% price shift). These findings are consistent with the global scramble for medical devices during the first waves of COVID-19, which drove up both demand and prices for infusion and transfusion equipment.

3.2 EU production scaled up substantially to meet surging global demand

EU domestic production of transfusion and infusion apparatus grew from approximately 1.20 billion items (€693.9 million) in 2015 to 1.76 billion items (€1,150.0 million) in 2025, representing volume growth of 47.3% and value growth of 65.7%. The production value exceeded €1.8 billion at its peak, confirming that the pandemic period catalysed a step-change in manufacturing capacity. This expansion underpinned the EU's ability to simultaneously grow exports and meet domestic demand.

3.3 Specialisation patterns confirm a concentrated but widening production base

The specialisation analysis for 2025 shows that Portugal (RSCA 0.53, RCA 3.24) and Hungary (RSCA 0.50, RCA 2.99) are the most specialised EU producers in relative terms, despite their modest overall shares. Germany (RSCA 0.25, RCA 1.66) and the Netherlands (RSCA 0.12, RCA 1.27) combine high absolute volumes with meaningful specialisation. At the other end, Finland, Estonia, Malta, Latvia, and Bulgaria show near-zero specialisation, indicating that production remains highly concentrated among a handful of member states — though the rise of Poland and the growth of Dutch re-export flows suggest the map is being redrawn.

Source: Market Structure — Specialisation

Conclusion

The EU trade market for transfusion and infusion apparatus (CN 90189050) expanded dramatically between 2015 and 2025. The Union consolidated its position as a major net exporter, with a trade surplus reaching €395 million by 2025, underpinned by robust production growth (47.3% in volume). However, this growth was not evenly distributed: the Netherlands and Poland emerged as major new trade hubs, while Germany's dominant position stabilised rather than expanded. On the import side, China remained the largest supplier, but the most striking development was the surge of the Dominican Republic as a sourcing origin — a shift that warrants monitoring for supply-chain risk. The COVID-19 pandemic in 2020 acted as a structural inflection point, triggering price shocks in key bilateral flows, catalysing production expansion, and likely accelerating the reconfiguration of global medical device supply chains. Looking ahead, the EU's rising export propensity (from 27% to 71%) signals growing exposure to global demand cycles, while declining import concentration (HHI from 1,743 to 1,162) offers some buffer against single-source supply disruptions.